4.3 Article

The lower limits for protein stability and foldability in primary hyperoxaluria type I

Journal

BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
Volume 1844, Issue 12, Pages 2355-2365

Publisher

ELSEVIER SCIENCE BV
DOI: 10.1016/j.bbapap.2014.10.010

Keywords

Protein kinetic stability; Protein denaturation energetics; Protein foldability; Misfolding disease; Differential scanning calorimetry; Molecular chaperone

Funding

  1. MINECO [BIO2012-34937, CSD-2009-00088, SAF2011-23933, RYC-2009-04147]
  2. Junta de Andalucia [P11-CTS-07187]
  3. European Union [FP7-REGPOT-CT2012-31637-IMBRAIN]
  4. FEDER

Ask authors/readers for more resources

Mutational effects on protein stability and foldability are important to understand conformational diseases and protein evolution. In this work, we perform a comprehensive investigation on the energetic basis underlying mutational effects on the stability of human alanine:glyoxylate aminotransferase (AGT). We study twenty two variants whose kinetic stabilities span over eleven orders of magnitude and are classified into two groups: i) ten naturally-occurring variants, including the most common mutations causing primary hyperoxaluria type I (PH1); and ii) twelve consensus variants obtained by sequence-alignment statistics. We show that AGT dimer stability determines denaturation rates, and mutations modulate stability by changes in the effective thermodynamic stability, the aggregation propensity of partially/globally unfolded states and subtle energetic changes in the rate-limiting denaturation step. In combination with our previous expression analyses in eukaryotic cells, we propose the existence of two lower limits for AGT stability, one linked to optimal folding efficiency (close to the major allele stability) and the other setting a minimal efficiency compatible with glyoxylate detoxification in vivo (close to the minor allele stability). These lower limits could explain the high prevalence of misfolding as a disease mechanism in PHI and support the use of pharmacological ligands aimed to increase AGT stability as therapies for this disease. (C) 2014 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available